Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions.

Area of Science:

• Oncology
• Biotechnology
• Biomedical Engineering

Background:

• Osteosarcoma is the most common primary bone malignancy in children and young adults.
• Current treatments for osteosarcoma have significant morbidity and a low survival rate, with stagnant 5-year survival for decades.
• There is a critical unmet need for effective second-line therapies and advanced preclinical models.

Purpose of the Study:

• To provide a comprehensive overview of state-of-the-art tissue-engineered and patient-specific models for osteosarcoma research.
• To highlight the potential of these advanced platforms for improving drug testing and treatment strategies.
• To address the limitations of current preclinical models in capturing osteosarcoma complexity.

Main Methods:

• Review of current literature on tissue-engineered and patient-specific models for osteosarcoma.
• Analysis of the application of these models in preclinical drug testing and therapy trials.
• Discussion of how these models account for tumor heterogeneity and bone microenvironment interactions.

Main Results:

• Tissue-engineered and patient-specific models represent a significant advancement in osteosarcoma preclinical research.
• These models offer more accurate representations of patient disease states compared to traditional models.
• They facilitate sophisticated drug-testing platforms that consider tumor complexity and microenvironment.

Conclusions:

• Advanced preclinical models, including tissue-engineered and patient-specific platforms, are crucial for improving osteosarcoma treatment outcomes.
• These models hold promise for accelerating the development of novel and effective therapies, particularly for second-line treatment.
• Enhancing preclinical research quality through these sophisticated platforms is essential for future patient benefit.